Pictet Asset Management
AKRO

Pictet Asset Management’s Akero Therapeutics AKRO Stock Holding History

Pictet Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-926,441
Closed -$44M – 2083
2025
Q3 		$44M Sell
926,441
-60,192
-6% -$2.91M 0.04% 346
2025
Q2 		$52.8M Buy
986,633
+671,922
+214% +$30.5M 0.05% 307
2025
Q1 		$12.7M Buy
+314,711
New +$13.3M 0.01% 598
2023
Q4 		– Sell
-399,285
Closed -$20.2M – 1963
2023
Q3 		$20.2M Buy
+399,285
New +$18.6M 0.02% 454

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Pictet Asset Management's AKRO Position: Q4 2025 in Review

Pictet Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 926,441 shares — an estimated $44M sold.

Pictet Asset Management first reported a position in AKRO in Q3 2023 and held it in 4 quarters. The position peaked at $52.8M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Pictet Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pictet Asset Management sold 926,441 Akero Therapeutics shares in Q4 2025, an estimated $44M.
  • Pictet Asset Management first reported a position in Akero Therapeutics in Q3 2023 and held it in 4 quarters.
  • Pictet Asset Management's Akero Therapeutics position peaked at $52.8M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Pictet Asset Management's 13F filing for Q4 2025, filed 29 Jan 2026.